This Viewpoint discusses obstacles that limit the use of biosimilar filgrastim in the United States compared with countries in the European Union and Japan and discusses strategies that might help biosimilar filgrastim use become more widespread.
https://ift.tt/2QcfTGE
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Publication date: June 2018 Source: Acta Biomaterialia, Volume 73 https://ift.tt/2kBbISt
-
http://bit.ly/2SylJiJ
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου